Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jun;84(12):1577–1585. doi: 10.1054/bjoc.2001.1836

Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?

S J T Jansen 1,2, J Kievit 1, M A Nooij 2, J C J M de Haes 3, I M E Overpelt 1,2, H van Slooten 4, E Maartense 5, A M Stiggelbout 1
PMCID: PMC2363690  PMID: 11401308

Abstract

When making decisions about adjuvant chemotherapy for early-stage breast cancer, costs and benefits of treatment should be carefully weighed. In this process, patients' preferences are of major importance. The objectives of the present study were: (1) to determine the minimum benefits that patients need to find chemotherapy acceptable, and (2) to explore potential preference determinants, namely: positive experience of the treatment, reconciliation with the treatment decision, and demographic variables. Preferences were elicited from patients scheduled for adjuvant chemotherapy (chemotherapy group: n = 38) before (T 1), during (T 2), and 1 month after chemotherapy (T 3), and were compared to responses from patients not scheduled for chemotherapy (no-chemotherapy group: n = 38). The patients were asked, for a hypothetical situation, to indicate the minimum benefit (in terms of improved 5-year disease-free survival) to find adjuvant chemotherapy acceptable. In the chemotherapy group, the median benefit was 1% at all 3 measurement points. In the no-chemotherapy group the attitude towards chemotherapy became more negative over time, although not statistically significantly so (T 1: 12%, T 2: 15%, T 3: 15%;P = 0.10). At all measurement points, the patients in the chemotherapy group indicated that they would accept chemotherapy for significantly (P< 0.01) less benefit than the patients in the no-chemotherapy group. Of the demographic variables, age was related to preferences, but only at T 2 and only in the no-chemotherapy group. The more positive attitude towards chemotherapy and the stability of preferences in the chemotherapy group indicated that reconciliation with the treatment decision was a more important determinant of patients' preferences than positive experience of the treatment. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: preferences, breast cancer, chemotherapy, cognitive dissonance reduction, shared decision-making

Full Text

The Full Text of this article is available as a PDF (152.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brundage M. D., Davidson J. R., Mackillop W. J. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol. 1997 Jan;15(1):330–340. doi: 10.1200/JCO.1997.15.1.330. [DOI] [PubMed] [Google Scholar]
  2. Cullen M. H., Billingham L. J., Cook J., Woodroffe C. M. Management preferences in stage I non-seminomatous germ cell tumours of the testis: an investigation among patients, controls and oncologists. Br J Cancer. 1996 Nov;74(9):1487–1491. doi: 10.1038/bjc.1996.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dodwell D. J. Adjuvant cytotoxic chemotherapy for early breast cancer: doubts and decisions. Lancet. 1998 May 16;351(9114):1506–1507. doi: 10.1016/s0140-6736(97)11247-8. [DOI] [PubMed] [Google Scholar]
  4. Elit L. M., Levine M. N., Gafni A., Whelan T. J., Doig G., Streiner D. L., Rosen B. Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecol Oncol. 1996 Sep;62(3):329–335. doi: 10.1006/gyno.1996.0244. [DOI] [PubMed] [Google Scholar]
  5. Fisher B., Dignam J., Wolmark N., DeCillis A., Emir B., Wickerham D. L., Bryant J., Dimitrov N. V., Abramson N., Atkins J. N. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997 Nov 19;89(22):1673–1682. doi: 10.1093/jnci/89.22.1673. [DOI] [PubMed] [Google Scholar]
  6. Jansen S. J., Stiggelbout A. M., Nooij M. A., Kievit J. The effect of individually assessed preference weights on the relationship between holistic utilities and nonpreference-based assessment. Qual Life Res. 2000;9(5):541–557. doi: 10.1023/a:1008917432368. [DOI] [PubMed] [Google Scholar]
  7. Kiebert G. M., Stiggelbout A. M., Leer J. W., Kievit J., de Haes H. J. Test-retest reliabilities of two treatment-preference instruments in measuring utilities. Med Decis Making. 1993 Apr-Jun;13(2):133–140. doi: 10.1177/0272989X9301300207. [DOI] [PubMed] [Google Scholar]
  8. Levine M. N., Gafni A., Markham B., MacFarlane D. A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med. 1992 Jul 1;117(1):53–58. doi: 10.7326/0003-4819-117-1-53. [DOI] [PubMed] [Google Scholar]
  9. Levine M. N., Guyatt G. H., Gent M., De Pauw S., Goodyear M. D., Hryniuk W. M., Arnold A., Findlay B., Skillings J. R., Bramwell V. H. Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol. 1988 Dec;6(12):1798–1810. doi: 10.1200/JCO.1988.6.12.1798. [DOI] [PubMed] [Google Scholar]
  10. Lindley C., Vasa S., Sawyer W. T., Winer E. P. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol. 1998 Apr;16(4):1380–1387. doi: 10.1200/JCO.1998.16.4.1380. [DOI] [PubMed] [Google Scholar]
  11. Llewellyn-Thomas H. A. Investigating patients' preferences for different treatment options. Can J Nurs Res. 1997 Fall;29(3):45–64. [PubMed] [Google Scholar]
  12. Llewellyn-Thomas H. A., Williams J. I., Levy L., Naylor C. D. Using a trade-off technique to assess patients' treatment preferences for benign prostatic hyperplasia. Med Decis Making. 1996 Jul-Sep;16(3):262–282. doi: 10.1177/0272989X9601600311. [DOI] [PubMed] [Google Scholar]
  13. McNeil B. J., Pauker S. G., Sox H. C., Jr, Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med. 1982 May 27;306(21):1259–1262. doi: 10.1056/NEJM198205273062103. [DOI] [PubMed] [Google Scholar]
  14. McQuellon R. P., Muss H. B., Hoffman S. L., Russell G., Craven B., Yellen S. B. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol. 1995 Apr;13(4):858–868. doi: 10.1200/JCO.1995.13.4.858. [DOI] [PubMed] [Google Scholar]
  15. Nieuwkerk P. T., Hajenius P. J., Van der Veen F., Ankum W. M., Wijker W., Bossuyt P. M. Systemic methotrexate therapy versus laparoscopic salpingostomy in tubal pregnancy. Part II. Patient preferences for systemic methotrexate. Fertil Steril. 1998 Sep;70(3):518–522. doi: 10.1016/s0015-0282(98)00213-1. [DOI] [PubMed] [Google Scholar]
  16. O'Connor A. M. Effects of framing and level of probability on patients' preferences for cancer chemotherapy. J Clin Epidemiol. 1989;42(2):119–126. doi: 10.1016/0895-4356(89)90085-1. [DOI] [PubMed] [Google Scholar]
  17. Palda V. A., Llewellyn-Thomas H. A., Mackenzie R. G., Pritchard K. I., Naylor C. D. Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making. J Clin Oncol. 1997 Oct;15(10):3192–3200. doi: 10.1200/JCO.1997.15.10.3192. [DOI] [PubMed] [Google Scholar]
  18. Pritchard K. Breast cancer: the real challenge. Lancet. 1997 Mar;349 (Suppl 1):sI24–sI26. doi: 10.1016/s0140-6736(97)90008-8. [DOI] [PubMed] [Google Scholar]
  19. Rajagopal S., Goodman P. J., Tannock I. F. Adjuvant chemotherapy for breast cancer: discordance between physicians' perception of benefit and the results of clinical trials. J Clin Oncol. 1994 Jun;12(6):1296–1304. doi: 10.1200/JCO.1994.12.6.1296. [DOI] [PubMed] [Google Scholar]
  20. Ravdin P. M., Siminoff I. A., Harvey J. A. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol. 1998 Feb;16(2):515–521. doi: 10.1200/JCO.1998.16.2.515. [DOI] [PubMed] [Google Scholar]
  21. Sainsbury R., Rider L., Smith A., MacAdam A. Does it matter where you live? Treatment variation for breast cancer in Yorkshire. The Yorkshire Breast Cancer Group. Br J Cancer. 1995 Jun;71(6):1275–1278. doi: 10.1038/bjc.1995.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Silvestri G., Pritchard R., Welch H. G. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ. 1998 Sep 19;317(7161):771–775. doi: 10.1136/bmj.317.7161.771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Siminoff L. A., Fetting J. H. Factors affecting treatment decisions for a life-threatening illness: the case of medical treatment of breast cancer. Soc Sci Med. 1991;32(7):813–818. doi: 10.1016/0277-9536(91)90307-x. [DOI] [PubMed] [Google Scholar]
  24. Slevin M. L., Stubbs L., Plant H. J., Wilson P., Gregory W. M., Armes P. J., Downer S. M. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ. 1990 Jun 2;300(6737):1458–1460. doi: 10.1136/bmj.300.6737.1458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Stiggelbout A. M., Kiebert G. M., de Haes J. C., Keizer H. J., Stoter G., de Wit R., Vermorken J. B., Leer J. W., Kievit J. Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: a decision analysis. Eur J Cancer. 1996 Dec;32A(13):2267–2274. doi: 10.1016/s0959-8049(96)00279-1. [DOI] [PubMed] [Google Scholar]
  26. Stiggelbout A. M., de Haes J. C., van de Velde C. J. Adjuvant chemotherapy in node negative breast cancer: patterns of use and oncologists' preferences. Ann Oncol. 2000 May;11(5):631–633. doi: 10.1023/a:1008379628579. [DOI] [PubMed] [Google Scholar]
  27. Whelan T. J., Levine M. N., Gafni A., Lukka H., Mohide E. A., Patel M., Streiner D. L. Breast irradiation postlumpectomy: development and evaluation of a decision instrument. J Clin Oncol. 1995 Apr;13(4):847–853. doi: 10.1200/JCO.1995.13.4.847. [DOI] [PubMed] [Google Scholar]
  28. Yellen S. B., Cella D. F., Leslie W. T. Age and clinical decision making in oncology patients. J Natl Cancer Inst. 1994 Dec 7;86(23):1766–1770. doi: 10.1093/jnci/86.23.1766. [DOI] [PubMed] [Google Scholar]
  29. Yellen S. B., Cella D. F. Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol. 1995 May;13(5):1255–1264. doi: 10.1200/JCO.1995.13.5.1255. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES